Abstract Details

Title Teriflunomide Use in Participants With Relapsing-Remitting MS Enrolled in the NARCOMS Registry

Topic Multiple Sclerosis

Presentation(s) P3 - Poster Session 3 (5:30 PM-6:30 PM)

Poster/Presentation
Number 15-088

Objective

To describe demographic/clinical characteristics of North American Research Committee on Multiple Sclerosis (NARCOMS) participants with relapsing-remitting MS (RRMS) receiving teriflunomide for 1 year.

Background

NARCOMS is a voluntary self-report registry that collects longitudinal health-related information from people with MS.

Design/Methods

Participants were identified from data collected in semi-annual update surveys between April 2012 and April 2017. Inclusion criteria were a diagnosis of RRMS, teriflunomide initiation and completion of a follow-up survey 1 year later. Demographic/clinical characteristics were analyzed and are summarized as descriptive statistics: sex, age, and disability level, as measured by the Patient-Determined Disease Steps (PDDS) scale, Performance Scales, and NARCOMS depression scale (DS).

Results

Out of 668 participants who ever received teriflunomide, 147 were eligible for analysis. Among them, 83.7% were female, 84.3% were white, and mean (SD) age at initiation was 46.3 (9.1) years, with a mean (SD) disease duration of 17.1 (8.8) years. At baseline, 91 participants (61.9%) reported no gait disability or early gait disability (PDDS ≤3); scores remained stable at follow-up in 90 (65.0%) participants, with 28 (19.0%) improving (data not available for n=7). Minimal to severe fatigue was reported at baseline by 122 (83.0%) participants; at follow-up, 77 (55.0%) participants reported no change, 34 (24.3%) reported improvement, and 25 (17.9%) reported worsening fatigue. At initiation, 81 (57.4%) respondents reported minimal or greater depression, and at follow-up 108 (73.5%) had stable or improved DS scores. One or more corticosteroid-treated relapses were listed by 22 (15.0%) participants in the 12 months before initiating teriflunomide and by 29 (19.7%) in the following 12 months.

Conclusions

Demographic/clinical characteristics of the teriflunomide-treated cohort were similar to those of the overall RRMS population in the NARCOMS Registry. After 1 year of teriflunomide treatment, most respondents reported stability or improvement of disability, fatigue, and depression.

Authors/Disclosures
Lobat Hashemi PRESENTER	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Robert J. Fox, MD, FAAN (Cleveland Clinic)	Dr. Fox has received personal compensation in the range of $500-$4,999 for serving as a Consultant for AB Science. Dr. Fox has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Fox has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for BMS. Dr. Fox has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for EMD Serono. Dr. Fox has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Genentech. Dr. Fox has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Immunic. Dr. Fox has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Fox has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi. Dr. Fox has received personal compensation in the range of $500-$4,999 for serving as a Consultant for TG Therapeutics. Dr. Fox has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Siemens. Dr. Fox has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Roche. Dr. Fox has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astoria Biologica. Dr. Fox has received personal compensation in the range of $500-$4,999 for serving as a Consultant for InnoCare Pharma. Dr. Fox has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Fox has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Immunic. Dr. Fox has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Fox has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AB Science. Dr. Fox has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Fox has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for BMS. The institution of Dr. Fox has received research support from National Institutes of Health. The institution of Dr. Fox has received research support from National MS Society. Dr. Fox has received publishing royalties from a publication relating to health care.
	No disclosure on file
Thomas Carattini	No disclosure on file
	No disclosure on file
Gary R. Cutter, PhD (University of Alabama At Birmingham)	Dr. Cutter has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for onsulting or Advisory Boards: Alexion, Antisense Therapeutics/Percheron, Avotres, Biogen, Clene Nanomedicine, Clinical Trial Solutions LLC, Endra Life Sciences, Cognito Therapeutics, Genzyme, Genentech, Immunic, Klein-Buendel Incorporated, Kyverna Therapeutics, Inc. , Linical, Merck/Serono, Noema, Neurogenesis, Perception Neurosciences, Protalix Biotherapeutics, Regeneron, Revelstone Consulting, Roche, SAB Biotherapeutics, Sapience Therapeutics, Scott&Scott LLP, Tenmile.. Dr. Cutter has received personal compensation in the range of $50,000-$99,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Data and Safety Monitoring Boards: Applied Therapeutics, AI therapeutics, AMO Pharma, Argenx, Astra-Zeneca, Avexis Pharmaceuticals, Bristol Meyers Squibb, CSL Behring, Cynata Therapeutics, DiamedicaTherapeutics, Horizon Pharmaceuticals, Immunic, Inhibrix, Karuna Therapeutics, Kezar Life Sciences, Medtronic, Merck, Meiji Seika Pharma, Mitsubishi Tanabe Pharma Holdings, Prothena Biosciences, Novartis, Pipeline Therapeutics (Contineum), Regeneron, Sanofi-Aventis, Teva Pharmaceuticals, United BioSource LLC, University of Texas Southwestern.. Dr. Cutter has received personal compensation in the range of $5,000-$9,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for JASN.

��ɫ��

��ɫ��